<WRAP group>
<WRAP center width-90%>
===== PD-L1 IHC BIOMARKER – NON-REPORTABLE =====

**Comment:** PD-L1 was requested; however, the result is **Non-Reportable** for the following reason(s):

  * **Fixation Requirements:** Validated only for tissue fixed in 10% NBF for 12–72 hours.
  * **Cellularity:** Sample lacks the minimum requirement of **100 viable tumor cells**.
  * **Pre-analytical Interference:** Incompatible with:
    * Non-NBF fixatives or sub-optimal fixation times.
    * Extended ischemic time.
    * Decalcification or microwave treatment.
  * **Assay Specificity:** PD-L1 assays (22C3, 28-8, SP263) are **not interchangeable** and cannot be substituted.
  * **Clinical Indications:**
    * **Unknown Primary:** Primary site must be known to determine the appropriate scoring system.
    * **Provincial Approval:** Testing is restricted to cancer types approved for funding in Alberta.

**Resources:**
  * [[https://www.albertahealthservices.ca/assets/programs/ps-1025651-drug-benefit-list.pdf|AHS Drug Benefit List]]
  * [[https://www.pdl1alberta.com|PD-L1 Alberta Portal]]

----
**Test ID:** %%MDHPDL1NONREPORTABLE%%
</WRAP>
</WRAP>

{{:MDHPDL1NONREPORTABLE.docx|MDHPDL1NONREPORTABLE}}